Evonik trims capex as Q2 free cash flow falls on weak demand

Evonik Industries reported a significant deterioration in its second-quarter performance, with free cash flow plummeting to negative €211 million from a positive €217 million year-over-year, alongside an 11% revenue decline to €3.50 billion and a 12% drop in adjusted EBITDA to €509 million. Citing weaker demand, adverse currency effects, and operational disruptions, the German specialty chemicals firm announced a €100 million reduction in 2025 capital expenditures. While maintaining its full-year adjusted EBITDA guidance, Evonik now anticipates results at the lower end of its €2.0 billion to €2.3 billion range, conditional on no further global economic slowdown.

Analysis

Evonik Industries (ETR:EVKn) reported a significant deterioration in its second-quarter financial performance, underscored by a sharp reversal in free cash flow to negative €211 million from a positive €217 million in the prior-year period. This decline, attributed to increased working capital and compensation payouts, prompted management to reduce 2025 capital expenditures by €100 million. The company's top and bottom lines were heavily impacted by cyclical and operational headwinds, with revenue declining 11% to €3.50 billion and adjusted EBITDA falling 12% to €509 million. Management cited weakening demand in May and June, adverse currency effects, and prolonged maintenance shutdowns as key drivers for the downturn, which also saw sales volumes fall 4%. While Evonik maintained its full-year adjusted EBITDA guidance, it now anticipates results at the lower end of the €2 billion to €2.3 billion range, and this forecast is critically dependent on the global economy not weakening further. Segment performance revealed broad-based weakness, with the Advanced Technologies division's flat EBITDA being propped up by a one-off license agreement, masking underlying demand issues in its Inorganics and Organics businesses.

Key Decisions for Investors

• Investors should closely scrutinize the company's ability to reverse its negative free cash flow, as the maintained guidance is highly conditional on a stable macroeconomic environment, posing a significant risk to future earnings.
• Given the broad-based demand weakness, operational disruptions, and the de facto guidance downgrade to the lower end of the range, a cautious or defensive stance on Evonik (ETR:EVKn) is warranted until there are clear signs of a demand recovery in its key end-markets.
• It is critical to look beyond headline figures, as the flat EBITDA in the Advanced Technologies segment was supported by a one-off income gain, masking underlying demand weakness and competitive pressures that could impact future profitability.